Eli Lilly's (NYSE:LLY) weight-loss drug Zepbound is now reportedly covered by Medicare for the treatment of obstructive sleep ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has announced the clearance of its investigational new drug (IND) application by ...

Short-term HRV is significantly associated with poor daytime psychomotor vigilance performance among both men and women with ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Researchers combine OCT imaging and computational fluid dynamics to accurately map upper airway obstructions, advancing sleep ...

The U.S. FDA has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea.

Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions associated with excess morbidity and mortality – – Obstructive ...

In the U.S., a large percentage of the population suffers from poor sleep quality and sleep disorders. Americans also eat too much fatty and processed food.

Although snoring or sleep apnea might suggest a neck size associated with heart failure risk, the study did not conclude that ...

Weight-loss medication like Semaglutide and Tirzepatide has seen a rise in demand, causing a boom in sales. This exploding ...